Robert Hudrick,   DO

Education

Philadelphia College of Osteopathic Medicine, PA
DO , 1988

Top of page

Honors and Awards

2006,   Family Medicine Educator of the Year Award - UMDNJ Family Medicine Residents

Top of page

Research Areas

Phase IV, Stratified, Randomized Prospective, Unblinded, Active Control Trial of Factive vs Biaxin XL for the Treatment of Community Acquired Pneumonia vs Amoxicillin/clavulanate for the Treatment of Acute Exacerbation of Chronic Bronchitis: Principal Investigator - August 2006 to present Oscient Pharmaceutical

(H7U-MC-IDBA-) Phase 3, Open-Label, Three-Group Parallel Study to Evaluate The Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type II Diabetes Treated with Once-Daily Insulin Glargine: Principal Investigator July 2006 to present Eli Lilly and Company

Assessing The Durability of Basil vs. Lispro Mix 25 Insulin Efficacy. The Durability of Twice-Daily Insulin Lispro mixture compared to Once Daily Insulin Glargine when added to Existing Oral Therapy - Type II diabetes and Inadequate Glycemic Control: Principal Investigator May 2006 to present Eli Lilly and Company

(H7U-MC-IDBA-) A Phase III, Open-Label, Parallel group Treatment Concordance Study to Compare Insulin Use and Its Effects on Glycemic Control in Patients with Type Ii Diabetes Mellitus: Principal Investigator May 2006 to present Eli Lilly and Company

Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorders: A Randomized Double-Blind Comparison with Placebo: Sub Investigator with Psychiatry Department Decemebr 2004 to February 2006 Eli Lilly and Company

Quetiapine Treatment for Symptoms Associated with Borderline Personality Disorder: Sub Investigator with Psychiatry Department (Dr. David Rissmiller) December 2004 to present Astra Zeneca

A 52 Week, Multi-Center, Double-Blind, Randomized, Withdrawal, parallel-group, placebo Controlled, Phase III Study of the Efficacy and Safety of Seroquel SR 50, 150, 300 mg/day as Monotherapy in the Maintenance of Patients with Major Depressive Disor: Sub Investigator with Psychiatry Department April 2006 to present AstraZeneca

A Randomized, double-blind, double-dummy, placebo-cntl, 4x4 factorial design trial to evaluate telmisartan 20, 40 and 80 mg tablets in combo with amlodipine 2.5, 5 and 10 mg capsules after eight weeks of treatment in patients with Stage I or II hyper: Sub Investigator with Psychiatry Department October 2005 to present Bochringer Ingelheim Pharmaceuticals, Inc.

Phase III, Open-Label, Non-Comparative Study of Complaints Associated with the Use of the Pre-filled Pen B When Used by Patients with Type 2 diabetes on Twice-Daily Insulin Therapy: Principal Investigator June 2005 to April 2006 Eli Lilly and Company

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastin (CRESTOR) 20mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein: Principal Investigator March 2005 to October 2005 Astra Zeneca

Randomized, Double-Blind, Multicenter Study to Compare Health Economic Outcomes of Telithromycin versus Azithromycin in Outpatients with Community Acquired Lower Respiratory Tract Infections Aventis : Principal Investigator February 2005 to present Aventis

Multi-center, open-label, flexible-dose Parallel-group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL) and risperidone in the long-term treatment of subjects or schizoaffective disorder: Sub-Investigator January 2004 to present Astra Zeneca

Phase III and IV clinical drug trials, Allegheny University Hospital : Sub-Investigator November 1995 - September 1997 Allegheny University Hospital

Top of page